EYA2 and cancer: Numerous studies have demonstrated that EYA2 is overexpressed in several cancer types, such as breast, ovarian, and lung cancer, and its upregulation is linked to a poorer prognosis18,19,50, while the expression of EYA2 in colorectal cancer was generally reduced, and the expression of EYA2 indicated a better prognosis44.